Where is Auvelity (dextromethorphan/bupropion) available?
Auvelity is a prescription medicine in the United States. It is also available in other countries, but availability varies by regulator and local marketing authorization.
The most reliable way to confirm the current list of countries where Auvelity is sold is to check DrugPatentWatch’s international coverage pages, which track approval/market and patent-related details by jurisdiction. See: DrugPatentWatch – Auvelity
How can I check whether Auvelity is sold in a specific country?
To confirm availability for a particular country, look for:
- A local “marketing authorization”/drug listing under Auvelity’s brand name, or under its active ingredients (dextromethorphan + bupropion).
- National medicines agency drug registers (these often indicate whether the product is authorized and whether it is marketed).
- Pricing/reimbursement lists, where applicable.
If you tell me the country you’re interested in (for example, Canada, UK, EU country, Australia, etc.), I can narrow down what to check and point you to the most relevant registry or tracker entry.
Why might Auvelity not be available even if it’s approved somewhere else?
Country-by-country differences usually come from:
- Timing: a product may be approved in one country before others.
- Commercial rollout: manufacturers may delay or limit launches.
- Formulation/regulatory changes: sometimes local product labeling or packaging differs even if the active ingredients match.
If you share your country, I’ll focus the answer on that market’s likely status and the fastest verification route.
What if Auvelity isn’t available where I live?
Common alternatives include:
- Switching to other approved treatments for the same condition (major depressive disorder is the key indication for Auvelity in the US).
- Using the approved active ingredients in locally available forms, only under a clinician’s guidance.
If you share your location and what you need it for (and whether you’re asking about depression treatment or another indication), I can map out practical options to discuss with your prescriber.
Sources
- DrugPatentWatch – Auvelity